Autoimmune diseases like lupus impact over 5 million patients globally, but treatment options remain limited. Now, decoding the once mysterious "dark genome" could bring new therapies. Over 90% of our DNA was once considered "junk"—but we’ve learned this dark matter regulates gene expression and human disease. This episode takes you to the pioneers who are unlocking the dark genome's potential to correct root causes of complex conditions like lupus. We'll chat with those illuminating this uncharted territory and developing novel approaches.

Guests include:

Rosana Kapeller, M.D., Ph.D., Co-Founder, President, & CEO at Rome Therapeutics
Steve Kafka, General Partner at S32
Keri Mastrogiacomo, mother of a Lupus patient
Katherine Cavanagh, Associate Investment Director at Cambridge Associates

This episode has named a Winner by the International Women’s Podcast Awards for their “A Moment of Visionary Leadership” category.

Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

S4:E5 Unlocking the Dark Genome for Lupus and Other Autoimmune Diseases